Top Stories

Dementia expert says evidence ‘wasn’t sufficient’ for approval

0


Dementia expert Dr. Jason Karlawish told CNBC he’s skeptical of the Food and Drug Administration’s approval of Biogen‘s Alzheimer’s disease drug, Aduhelm, saying “the evidence to approve the drug wasn’t sufficient.”

“Another study is needed to establish whether this drug, in fact, is effective. Unfortunately, the FDA approved the drug for marketing, although they also do want another study,” the co-director of the Penn Memory Center at the University of Pennsylvania said on Monday following the agency’s formal OK.

The FDA’s approval marks the first new treatment for Alzheimer’s in nearly two decades. Alzheimer’s is a progressive neurodegenerative disorder that slowly destroys memory and…



Source cnbc.com

0 0 votes
Article Rating

Reddit mania, inflation risks are recipe for serious sell-off: BTIG

Previous article

Kroger to hire 10,000 workers, hiring event set for Thursday

Next article

You may also like

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

More in Top Stories